OXISTAT (oxiconazole nitrate) by ANI Pharmaceuticals is clinical pharmacology pharmacokinetics the penetration of oxiconazole nitrate into different layers of the skin was assessed using an in vitro permeation technique with human skin. First approved in 1992.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
OXISTAT (oxiconazole nitrate) is a topical imidazole antifungal agent approved in 1992 for treatment of dermatophyte and yeast infections of the skin. It works by inhibiting ergosterol biosynthesis, disrupting fungal cell membrane integrity. The drug is formulated as a cream and lotion for direct application to affected skin areas.
Mature topical dermatology franchise with minimal Part D penetration signals limited commercial expansion opportunities and small support infrastructure.
CLINICAL PHARMACOLOGY Pharmacokinetics The penetration of oxiconazole nitrate into different layers of the skin was assessed using an in vitro permeation technique with human skin. Five hours after application of 2.5 mg/cm of oxiconazole nitrate cream onto human skin, the concentration of…
Worked on OXISTAT at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on OXISTAT offers limited career growth; the product is a mature, low-revenue topical asset with zero linked job openings and imminent loss of exclusivity. Positions on this franchise are typically maintenance-focused rather than strategic, offering modest compensation and reduced advancement potential.